Difference between revisions of "Team:SDU-Denmark/Tour34"

 
(15 intermediate revisions by 3 users not shown)
Line 6: Line 6:
  
 
<h1 align="center">Entrepreneurship</h1>
 
<h1 align="center">Entrepreneurship</h1>
 
+
<div class="thumb tright">
 +
<div class="thumbinner" style="width:315px; height:235px;">
 +
<a class="popupImg alignRight" style="width:310px" target="_blank" href="https://static.igem.org/mediawiki/2015/d/da/SDU2015_PFD_big.png" title="">
 +
  <img src="https://static.igem.org/mediawiki/2015/b/b9/SDU2015_PFD_thumbnail.png" style="width:310px"/></img></a>
 +
  <div class="thumbcaption"> Figure 1: Process Flow Diagram (PFD)  </div>
 +
</div>
 +
</div>
 
<p>
 
<p>
<span class="intro">This year’s</span> team has decided to enter the manufacturing track. This was due to our excitement of the applicability of our project. We feel strongly, that the need of a replacement for monoclonal antibodies and not least the opportunity to reduce usage of laboratory animals in productions, should be explored on an industrial level.
+
<span class="intro">We as a team</span> has decided to enter the manufacturing track. This was due to our excitement of the applicability of our project. We feel strongly, that the need of a replacement for mAbs and not least the opportunity to reduce usage of laboratory animals, should be explored on an industrial level.
 
</p>
 
</p>
  
  
<h1 align="center" style="opacity: 1;"> Process Design</h1>
 
 
<p>
 
<div class="thumb tright">
 
<div class="thumbinner" style="width:315px; height:415px;">
 
<a class="popupImg alignRight" style="width:310px" target="_blank" href="https://static.igem.org/mediawiki/2015/6/63/SDU2015_PFD_withtext.png" title="">
 
  <img src="https://static.igem.org/mediawiki/2015/d/de/SDU2015_pic_PFD1.png" style="width:310px"/></img></a>
 
  <div class="thumbcaption"> <i> Figure 1:</i> Process Flow Diagram (PFD)  </div>
 
</div>
 
</div>
 
 
</p>
 
  
<p> <span class="intro">The aim</span> of P. A. S. T. is to cater to customers with very specific needs. Therefore it has been decide to design several small-scale operations, which will allow the company to efficiently fill changing orders without accumulating large stocks of product.  
+
<p> <span class="intro">The aim</span> of PAST is to cater to customers with very specific needs. Therefore it has been decided to design several small-scale operations, which will allow the company to efficiently fill changing orders without accumulating large stocks.  
It has not been possible to determine any values for the process design experimentally, therefore estimates has been made using data obtained on proteins considered to be as close in properties as possible to the peptide aptamers. Protocols and research papers have been extrapolated linearly, which is most often not possible, therefore experiments should be conducted on both laboratory and pilot scale, and this proposal should only be taken as an indicator of the feasibility and competitiveness of the operation, and thereby the validity of carrying out the necessary experiments.  
+
It has not been possible to determine any values for the process design experimentally, therefore estimates has been made using data obtained on proteins considered to be as close in properties as possible to the peptide aptamers. Protocols and research papers have been extrapolated linearly, which is most often not possible. Therefore experiments should be conducted on both laboratory and pilot scale, and this proposal should only be taken as an indicator of the feasibility and competitiveness of the operation, and thereby the validity of carrying out the necessary experiments.  
 
Below is our process design. Click the boxes to dig deeper into each section. </p>
 
Below is our process design. Click the boxes to dig deeper into each section. </p>
  
Line 40: Line 34:
 
   <img src="https://static.igem.org/mediawiki/2015/d/d8/SDU2015_A1_Thumbnail.png" style="width:450px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/d/d8/SDU2015_A1_Thumbnail.png" style="width:450px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 2:</i> A1: Autoclave  </div>
+
   <div class="thumbcaption">Figure 2: Autoclave A1 </div>
 
</div>
 
</div>
 
</div>
 
</div>
  
<span class="intro">Before the fermentation</span> can begin, the substrate has to be sterilized to eliminate contamination of the  
+
<span class="intro">Before the fermentation</span> can begin, the substrate must be sterilized to avoid contamination of the  
  
fermentation broth, which is necessary in spite of selection by antibiotics. For this procedure a batch  
+
fermentation broth. For this procedure a batch  
  
 
sterilization has been chosen. To ensure sterility the feed is heated to 121 [°C], the pressure set at 2 [bar] and the  
 
sterilization has been chosen. To ensure sterility the feed is heated to 121 [°C], the pressure set at 2 [bar] and the  
Line 54: Line 48:
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
 
Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002
 
Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002
</span> This was simulated in Aspen Plus using the BK10 method, only the  
+
</span> This was simulated in Aspen Plus using the BK10 method, and only the  
  
compounds available in the database was considered. The simulation showed a volume of the autoclave of  
+
compounds available in the database were considered. The simulation showed a volume of the autoclave of  
  
26.6 [L] and a heat duty per batch of 48,483 [kJ/batch]. The substrate consist of Water (H<sub>2</sub>O), Glucose,  
+
26.6 [L] and a heat duty of 48,483 [kJ/batch]. The substrate consist of Water (H<sub>2</sub>O), Glucose,  
  
 
Ammonium chloride (NH<sub>4</sub>Cl), Monopotassium phosphate (KH<sub>2</sub>PO<sub>4</sub>), Epsom salt (MgS·7 H<sub>2</sub>O), Calcium chloride dihydrate (CaCl<sub>2</sub>·2H<sub>2</sub>O),  
 
Ammonium chloride (NH<sub>4</sub>Cl), Monopotassium phosphate (KH<sub>2</sub>PO<sub>4</sub>), Epsom salt (MgS·7 H<sub>2</sub>O), Calcium chloride dihydrate (CaCl<sub>2</sub>·2H<sub>2</sub>O),  
  
Ironsulphate (FeSO<sub>4</sub>), L-arganine·HCl, tracemetals and Ampicilin, the composition can be seen in the table. The  
+
Ironsulphate (FeSO<sub>4</sub>), L-arganine·HCl, tracemetals and Ampicilin, the composition can be seen in table 1. The  
  
amount and composition of the substrate was based on a research article, and the values were scaled
+
amount and composition of the substrate was based on a research artic <span class="sourceReference">le.</span>.  
 
+
linear<span class="sourceReference">ly</span>.  
+
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 117: Line 109:
 
   <img src="https://static.igem.org/mediawiki/2015/8/89/SDU2015_E1_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/8/89/SDU2015_E1_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 3:</i> E1: Heat exchanger  </div>
+
   <div class="thumbcaption">Figure 3: Heat exchanger E1 </div>
 
</div>
 
</div>
 
</div>
 
</div>
 
<p>
 
<p>
The substrate has to be cooled to 37 [°C], not only to ensure the survival of the cells in the inoculum, but also
+
To avoid a flash occurring in the fermenter and ensure the survivel of cells, the substrate has to be cooled to 37 .<span class="sourceReference">[°C]</span>.  
 
+
to lower the pressure to avoid a flash occurring in the ferment<span class="sourceReference">er</span>.  
+
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 131: Line 121:
 
this temperature, though growth at lower temperatures have been shown to decrease the amount of  
 
this temperature, though growth at lower temperatures have been shown to decrease the amount of  
  
inclusion bodies formed. It has to be shown at a later point if lower temperatures and the following  
+
inclusion bodies formed. It has to be investigated at a later point if lower temperatures and the following  
  
 
prolongation of cycle time, could lead to an increase in product<span class="sourceReference">ion</span>.  
 
prolongation of cycle time, could lead to an increase in product<span class="sourceReference">ion</span>.  
Line 190: Line 180:
 
   <img src="https://static.igem.org/mediawiki/2015/9/95/SDU2015_R1.1_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/9/95/SDU2015_R1.1_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 4:</i> R1.1: Batch fermentor </div>
+
   <div class="thumbcaption">Figure 4: Batch fermentation </div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 199: Line 189:
 
   <img src="https://static.igem.org/mediawiki/2015/e/e5/SDU2015_Entrepreneurship_scaleup_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/e/e5/SDU2015_Entrepreneurship_scaleup_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 5:</i> Illustration of the scale up process </div>
+
   <div class="thumbcaption"> Figure 5: Illustration of the scale up proce <span class="sourceReference">ss</span>.
 +
<span class="tooltip">
 +
  <span class="tooltipHeader">Reference:</span>
 +
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
 +
</span> </div>
 
</div>
 
</div>
 
</div>
 
</div>
  
Fermentation is carried out under two conditions, in this first phase growth is carried out as a batch until
+
Fermentation is carried out under two conditions. In this first phase growth is carried out as a batch until
  
glucose is depleted, this will take approximately 13 [h]. After which cells will be grown to high densities in a  
+
glucose is depleted, and will take approximately 13 [h]. After which, cells will be grown to high densities in a  
  
 
fed-batch. One hindrance for accumulation of high biomass concentrations is the formation of inhibitors as  
 
fed-batch. One hindrance for accumulation of high biomass concentrations is the formation of inhibitors as  
  
acetate. By restricting the carbon source this formation can be reduced greatly, which can be viewed in the
+
acetate. By restricting the carbon source this formation can be reduced greatly, which can be viewed in  
  
figure. The figure describes the experimental results presented in the research paper used for estimates.  
+
figure 5. The figure describes the experimental results presented in the research paper used for estimates.  
  
The inoculum is scale linearly as in the case of the substrate, therefore the same cell concentration is kept  
+
The inoculum is scale linearly as in the case of the substrate. Therefore the same cell concentration is kept  
  
 
and the time will not be affected. The fed-batch and induction will be discussed further bel<span class="sourceReference">ow</span>.  
 
and the time will not be affected. The fed-batch and induction will be discussed further bel<span class="sourceReference">ow</span>.  
Line 258: Line 252:
 
<br>
 
<br>
 
<br><br><br><br><br><br><br><br>
 
<br><br><br><br><br><br><br><br>
 +
<br><br><br><br><br><br><br>
 
   </div>
 
   </div>
  
Line 268: Line 263:
 
   <img src="https://static.igem.org/mediawiki/2015/b/b8/SDU2015_A2_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/b/b8/SDU2015_A2_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 6:</i> A2: Autoclave </div>
+
   <div class="thumbcaption">Figure 6: Autoclave A2 </div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 275: Line 270:
 
The substrate used for the fed-batch phase of the fermentation is sterilized in A2.  The same type of  
 
The substrate used for the fed-batch phase of the fermentation is sterilized in A2.  The same type of  
  
sterilization and conditions as in the A1 are chosen. The autoclave was simulated in Aspen Plus as well,
+
sterilization and conditions as in the A1 are chosen. Simulation in Aspen Plus  
  
yielding a volume of the autoclave of 16.2 [L] and a heat duty of 7.457 [kJ/batch]. The composition of the  
+
yielded a volume of 16.2 [L] and a heat duty of 7.457 [kJ/batch]. The composition of the  
  
substrate can be viewed in table, it should be noted that the concentration of glucose is considerably
+
substrate can be viewed in table 4. It should be noted that in order to avoid
  
higher than in S1. This is to avoid dilution of the cell concentrati<span class="sourceReference">on</span>.  
+
dilution of the cell concentration, the concentration of glucose is considerably
 +
 
 +
higher than in <span class="sourceReference">S1.</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 319: Line 316:
 
<p>
 
<p>
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:255px; height:150px;">
+
<div class="thumbinner" style="width:255px; height:170px;">
 
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/6/63/SDU2015_E2_big.png" title="E2">
 
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/6/63/SDU2015_E2_big.png" title="E2">
 
   <img src="https://static.igem.org/mediawiki/2015/4/4a/SDU2015_E2_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/4/4a/SDU2015_E2_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 7:</i> E2: Heat exchanger </div>
+
   <div class="thumbcaption">Figure 7: Heat exchanger E2 </div>
 
</div>
 
</div>
 
</div>
 
</div>
  
The substrate of the fed-batch has to be cooled as in the case of E1, the same conditions are chosen, see  
+
The substrate of the fed-batch has to be cooled as in the case of E1. The same conditions are chosen, see  
  
table, and the exchanger was simulated in Aspen Plus. The simulation showed that 348 [L/batch] cooling  
+
table 5, and the exchanger was simulated in Aspen Plus. The simulation showed that 348 [L/batch] cooling  
  
 
water is needed, and that the heat duty is 4,016,502 [kJ/batch].  
 
water is needed, and that the heat duty is 4,016,502 [kJ/batch].  
Line 372: Line 369:
 
   <img src="https://static.igem.org/mediawiki/2015/2/22/SDU2015_R1.2_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/2/22/SDU2015_R1.2_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 8:</i> R1.2 Fed-batch fermentation</div>
+
   <div class="thumbcaption">Figure 8: Fed-batch fermentation</div>
 
</div>
 
</div>
 
</div>
 
</div>
As mentioned above the fed-batch facilitate high yield of dry cells, the experimental data from the research
+
As mentioned above, the fed-batch facilitate high yield of dry cells. The experimental data from the research
  
paper showed that a concentration of 75 [g dry cells/L] was reached after 27 [h], this was deemed an  
+
paper showed that a concentration of 75 [g dry cells/L] was reached after 27 [h]. This was deemed an  
  
appropriate level to start induction. The results also showed, that substrate was fed in a rate, where  
+
appropriate level to start induction. The results also showed that substrate was fed in a rate, where  
  
glucose did not accumulate in the broth, and furthermore the levels of acetate after an initial rise was non-
+
glucose did not accumulate in the broth, and furthermore that the levels of acetate after an initial rise was non-
  
existent in the end of the fed-batch phase, see figure under R1.1: Batch fermentation. The composition of  
+
existent in the end of the fed-batch phase, see figure 5: Batch fermentation. The composition of  
  
the fermentation broth before induction can be viewed in <span class="sourceReference">table</span>.  
+
the fermentation broth before induction can be viewed in <span class="sourceReference">table 6</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 439: Line 436:
 
   <img src="https://static.igem.org/mediawiki/2015/6/62/SDU2015_R1.3_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/6/62/SDU2015_R1.3_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 9:</i> R1.3 Induction</div>
+
   <div class="thumbcaption">Figure 9: Induction</div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 445: Line 442:
 
Now the production of peptide aptamers can begin. The production is induced by Isopropyl-β-D-
 
Now the production of peptide aptamers can begin. The production is induced by Isopropyl-β-D-
  
thiogalactoside (IPTG), which is added to a concentration of 2 [mM]. Since IPTG is a carbon source it is
+
thiogalactoside (IPTG), which is added to a concentration of 2 [mM]. The target concentration of product will be discussed during the
  
assumed, that it will be depleted fully. The target concentration of product will be discussed during the  
+
elution phase of the product recovery. The composition at start of induction and of the fermentation broth
  
elution phase of the product recovery, the composition at start of induction and of the fermentation broth
+
can be viewed in table 7. It was shown that inducing in the late log phase let to
  
can be viewed in table. The induction time is 4 [h], it was shown that inducing in the late log phase let to
+
high yields of production, reducing the production phase to 4 [h]. Another benefit of the shortened residence time of the product, which reduces the risk of degradation by for example proteases. In the research paper the yield of product was reported to be  
 
+
high yields of product. Another benefit is the shortened residence time of the product, which reduces the  
+
 
+
risk of degradation by for example proteases. In the research paper the yield of product was reported to be  
+
  
 
56 [mg/L] and the dry cell concentration was 92 <span class="sourceReference">[g/L]</span>.  
 
56 [mg/L] and the dry cell concentration was 92 <span class="sourceReference">[g/L]</span>.  
Line 514: Line 507:
 
   <img src="https://static.igem.org/mediawiki/2015/9/9e/SDU2015_C1.1_big.png" style="width:230px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/9/9e/SDU2015_C1.1_big.png" style="width:230px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 10:</i> C1.1 Collum 1</div>
+
   <div class="thumbcaption"> Figure 10: Equilibration of C1</div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 522: Line 515:
 
to be fluidized. The fluidization process is described in greater detail during the next step. An important  
 
to be fluidized. The fluidization process is described in greater detail during the next step. An important  
  
parameter for the creating of a stable bed is viscosities, should viscosities of the different buffers used vary  
+
parameter for the creation of a stable bed is viscosity, should viscosities of the different buffers used vary  
  
in a degree that destabilizes the bed an inert viscous liquid will be add to the buf<span class="sourceReference">fer</span>.  
+
in a degree that destabilizes the bed an inert viscous liquid will be add<span class="sourceReference">ed.</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 534: Line 527:
 
The expansion is achieved be applying 10 bed volumes (BV) of column buffer (20 mM (4-(2-
 
The expansion is achieved be applying 10 bed volumes (BV) of column buffer (20 mM (4-(2-
  
Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt) Na-HEPES, 500 mM Sodium chloride (NaCl))at a
+
Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt) (Na-HEPES) and 500 mM Sodium chloride  
  
flowrate of 300 [cm/h], which is recommended, though flows between 200 and 400 [cm/h] has been shown  
+
(NaCl)) at a flowrate of 300 [cm/h], which is recommended, though flows between 200 and 400 [cm/h] has been shown  
  
sufficient. A protocol for purifying Intein recommends several different flowrates throughout the product
+
sufficient. The composition can be viewed in
  
recovery, but it has been decided to use the recommended flow for the expanded bed adsorption (EBA),
+
table 8. Determination of the BV relies on the production (see
  
since the most difficult step in the purification is creating a stable bed. The composition can be viewed in
+
equation 1), it has been decided to produce 2 [g/batch] of the peptide aptamer. This decision will be  
  
table. The decision to produce approximately 2 g of peptide aptamer per batch will be elaborated in the  
+
elaborated in the decription of the elution step  
 
+
<span class="sourceReference">(C1.4).</span>  
elution step, though it is determining the BV, which can be calculated from equation <span class="sourceReference">1:</span>  
+
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 562: Line 554:
 
To estimate the time needed for equilibration, we need to estimate the volume of the column. Expansion is  
 
To estimate the time needed for equilibration, we need to estimate the volume of the column. Expansion is  
  
reported to be 2-3 BV, therefore an expansion of 2.5 was chosen for calculations. Thus the column should  
+
reported to be 2-3 BV, therefore an expansion of 2.5 BV was chosen for calculations. Thus the column should  
  
 
be able to contain approximately 3 L. A column with a diameter of 50 [mm] is deemed to be appropriate for  
 
be able to contain approximately 3 L. A column with a diameter of 50 [mm] is deemed to be appropriate for  
Line 607: Line 599:
 
   <img src="https://static.igem.org/mediawiki/2015/3/36/SDU2015_C1.2_onesize.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/3/36/SDU2015_C1.2_onesize.png" style="width:250px"/>   
 
</a>
 
</a>
<div class="thumbcaption"><i>Figure 11:</i> Collum 2.</div>
+
<div class="thumbcaption">Figure 11: Application of fermentation broth and wash of C1</div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 613: Line 605:
 
The benefit of the EBA is, that the fluidization leaves space between the beads for particulate matter to
 
The benefit of the EBA is, that the fluidization leaves space between the beads for particulate matter to
  
pass through, thereby rendering the solid separation steps of traditional product recovery unnecessary.  
+
pass through. Rendering the solid separation steps of traditional product recovery unnecessary.  
  
This type of chromatography has been reported to be a one-step purification, if further purification is  
+
This type of chromatography has been reported to be a one-step purification. Another benefit is the time reduction before the protein
  
needed see what’s next. A further benefit is, that the time before the peptide aptamers are bound to the  
+
is bound to the beads, further reducing the residence ti<span class="sourceReference">me.</span>.  
 
+
beads is shortened, as in the case of induction, this leads to the shortest residence time poss<span class="sourceReference">ible</span>.  
+
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 634: Line 624:
 
design of the beads. In a stable bed the beads follow a Gaussian distribution. This is obtained by varying the  
 
design of the beads. In a stable bed the beads follow a Gaussian distribution. This is obtained by varying the  
  
density of the beads. Therefore the ordinary agarose beads are fitted with inert cores of varying diameters.  
+
density of the beads. Therefore the ordinary agarose beads are fitted with inert cores of varying diameters.
 
+
An unstable bed leads to risk of turbulence or  
The differing weights will ensure the correct distribution. An unstable bed leads to risk of turbulence or  
+
  
 
channelling, which will say that the feed does not have sufficient contact with the beads to bind the  
 
channelling, which will say that the feed does not have sufficient contact with the beads to bind the  
Line 648: Line 637:
 
</span>
 
</span>
 
</p>
 
</p>
In this step the fermentation broth is applied first, after which all impurities is washed out of the column by
+
In this step the fermentation broth is applied first, after which all impurities are washed out of the column by
  
applying 20 BV of column buffer. The streams can be viewed in ta<span class="sourceReference">ble</span>.  
+
applying 20 BV of column buffer. The streams can be viewed in ta<span class="sourceReference">ble 9</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 705: Line 694:
 
   <img src="https://static.igem.org/mediawiki/2015/4/4a/SDU2015_A3_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/4/4a/SDU2015_A3_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 12:</i> A3: Autoclave</div>
+
   <div class="thumbcaption">Figure 12: Autoclave A3</div>
 
</div>
 
</div>
 
</div>
 
</div>
  
At this time all waste containing cells has been gathered, and it is ready for sterilization. It is assumed that  
+
It is assumed that  
  
all cells will be contained in S10 and S12. The conditions during sterilization is the same as that of the A1  
+
all cells will be contained in S10 and S12 and should be sterilized.. The conditions during sterilization is the same as that of the A1  
  
and A2. The simulation in Aspen Plus yields the following results: a volume of the autoclave of 80.2 [L] and  
+
and A2. The simulation in Aspen Plus yields the following results: a volume of 80.2 [L] and  
  
 
a heat duty of 167,301,000 [kJ/batch].
 
a heat duty of 167,301,000 [kJ/batch].
Line 764: Line 753:
 
   <img src="https://static.igem.org/mediawiki/2015/2/29/SDU2015_E3_thumbnail.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/2/29/SDU2015_E3_thumbnail.png" style="width:250px"/>   
 
</a>
 
</a>
<div class="thumbcaption"><i>Figure 13:</i> E3: Heat exchanger</div>
+
<div class="thumbcaption">Figure 13: Heat exchanger E3</div>
 
</div>
 
</div>
 
</div>
 
</div>
 
Before releasing the waste stream to the ordinary waste water system, the pressure has to be lowered.  
 
Before releasing the waste stream to the ordinary waste water system, the pressure has to be lowered.  
  
Therefore the stream is cooled to  to ensure that the waste leaves as a liquid. This unit was simulated in  
+
Therefore the stream is cooled to ensure that the waste leaves as a liquid. This unit was simulated in  
  
Aspen Plus, the results are as follows: that 14854 [L/batch] cooling water is needed, and that the heat duty  
+
Aspen Plus, the results are as follows: 14,854 [L/batch] cooling water is needed, and the heat duty  
  
is 172,581,480 [kJ/batch]. The composition does not change and can be viewed in table under sterilization.  
+
is 172,581,480 [kJ/batch]. The composition does not change and can be viewed in table 11.  
  
 
</p>
 
</p>
Line 823: Line 812:
 
   <img src="https://static.igem.org/mediawiki/2015/f/f5/SDU2015_C1.3_onesize.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/f/f5/SDU2015_C1.3_onesize.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 14:</i> Collum 3</div>
+
   <div class="thumbcaption">Figure 14: Cleavage of Intein</div>
 
</div>
 
</div>
 
</div>
 
</div>
  
The aim of this step is to cleave the Intein and release the peptide aptamer. This is achieved by flushing the  
+
In this step Intein selfcleaves releasing the peptide aptamer. This is achieved by flushing the  
  
 
column with 3 BV of cleavage buffer (20 mM Na-HEPES, 500 mM NaCl, 50 mM threo-1,4-Dimercapto-2,3-
 
column with 3 BV of cleavage buffer (20 mM Na-HEPES, 500 mM NaCl, 50 mM threo-1,4-Dimercapto-2,3-
Line 833: Line 822:
 
butanediol (DTT)), where after the resin is left at room temperature for 16 h, therefore it is assumed that all  
 
butanediol (DTT)), where after the resin is left at room temperature for 16 h, therefore it is assumed that all  
  
buffer leaves the column as waste in this step. It has been reported, that product recovery is above 95% at 
+
buffer leaves the column as waste in this step. It has been reported, that product recovery is above 95%, therefore it is assumed that 95% will be cleav
  
in this time periode, therefore it is assumed that 95% can be cleaved at . The beads used to bind intein is
+
<span class="sourceReference">ed.</span>.  
 
+
chi<span class="sourceReference">tin</span>.  
+
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 882: Line 869:
 
   <img src="https://static.igem.org/mediawiki/2015/5/5f/SDU2015_C1.4_onesize.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/5/5f/SDU2015_C1.4_onesize.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 15:</i> Collum 4</div>
+
   <div class="thumbcaption"> Figure 15: Elution of peptide aptamer</div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 906: Line 893:
 
</p>
 
</p>
 
<p>
 
<p>
The aim of PAST is to have several small set-ups, that will allow us to change production according to order.
 
  
Due to these changing productions and the decision to release the broth at a predefined viscosity,  
+
 
 +
Due to the changing productions and the decision to release the broth at a predefined viscosity,  
  
 
concentrations of the product in each batch will fluctuate. Therefore the aim is to produce 2.5 g of the  
 
concentrations of the product in each batch will fluctuate. Therefore the aim is to produce 2.5 g of the  
Line 914: Line 901:
 
peptide aptamer per batch. The wanted concentration is reached by measuring the concentration at the  
 
peptide aptamer per batch. The wanted concentration is reached by measuring the concentration at the  
  
release of the broth and adjust the elution in the product recovery accordingly. This determines the volume  
+
release of the broth and adjust the elution accordingly. This determines the volume  
  
of the elution, the result can be viewed in table. Elution is performed with column buffer. If this buffer is  
+
of the elution, the result can be viewed in table 13. Elution is performed with column buffer. If this buffer is  
  
 
not suited for storage, it can be changed by dialysis, though for now it is assumed appropr<span class="sourceReference">iate</span>.  
 
not suited for storage, it can be changed by dialysis, though for now it is assumed appropr<span class="sourceReference">iate</span>.  
Line 964: Line 951:
 
   <img src="https://static.igem.org/mediawiki/2015/0/0a/SDU2015_C1.5_onesize.png" style="width:250px"/>   
 
   <img src="https://static.igem.org/mediawiki/2015/0/0a/SDU2015_C1.5_onesize.png" style="width:250px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 16:</i> Collum 5</div>
+
   <div class="thumbcaption">Figure 16: Regeneration of the column</div>
 
</div>
 
</div>
 
</div>
 
</div>
 
The last step of the product recovery is regeneration of the column, which prepares it for the next batch. It  
 
The last step of the product recovery is regeneration of the column, which prepares it for the next batch. It  
  
is reported that the resin can be reused 4-5 times, it is assumed that 4 times is appropriate. Regeneration is  
+
has been reported that the resin can be reused 4-5 times, it is assumed that 4 times is appropriate. Regeneration is  
  
performed by washing the bed with 3 volumes of stripping solution (0.3 M Sodium hydroxide (NaOH)) and  
+
performed by washing the bed with 3 BV of stripping solution (0.3 M Sodium hydroxide (NaOH)) and  
  
then leaving the bed to soak for 30 minutes. After which the column is washed 7 additional times with the  
+
then leaving the bed to soak for 30 minutes. After which the column is washed with additional 7 BV of the  
  
stripping solution, followed with 20 bed volumes of water. Lastly 5 bed volumes of column buffer is app<span class="sourceReference">lied</span>.  
+
stripping solution, followed with 20 BV of water. Lastly 5 BV of column buffer is app<span class="sourceReference">lied</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 1,010: Line 997:
  
 
<div class="thumb" align="center">
 
<div class="thumb" align="center">
<div class="thumbinner" style="width:755px; height:300px;">
+
<div class="thumbinner" style="width:355px; height:180px;">
<a class="popupImg alignRight" style="width:750px" target="_blank" href="https://static.igem.org/mediawiki/2015/7/7f/SDU2015_ProcessDesign_Timeline_kopi.png" title="Timeline">
+
<a class="popupImg alignRight" style="width:350px" target="_blank" href="https://static.igem.org/mediawiki/2015/0/06/SDU2015_Entrepreneuship_Timeline.jpg" title="Timeline">
   <img src="https://static.igem.org/mediawiki/2015/7/7f/SDU2015_ProcessDesign_Timeline_kopi.png" style="width:750px"/>   
+
   <img src="https://static.igem.org/mediawiki/2015/0/06/SDU2015_Entrepreneuship_Timeline.jpg" style="width:350px"/>   
 
</a>
 
</a>
   <div class="thumbcaption"> <i> Figure 17:</i> Timeline illustrating the entire process from autoclave to product. </div>
+
   <div class="thumbcaption">Figure 17: Timeline illustrating the entire process. </div>
 
</div>
 
</div>
 
</div>
 
</div>

Latest revision as of 16:15, 4 October 2015

"Design is not just what it looks like and feels like. Design is how it works." - Steve Jobs

Entrepreneurship

Figure 1: Process Flow Diagram (PFD)

We as a team has decided to enter the manufacturing track. This was due to our excitement of the applicability of our project. We feel strongly, that the need of a replacement for mAbs and not least the opportunity to reduce usage of laboratory animals, should be explored on an industrial level.

The aim of PAST is to cater to customers with very specific needs. Therefore it has been decided to design several small-scale operations, which will allow the company to efficiently fill changing orders without accumulating large stocks. It has not been possible to determine any values for the process design experimentally, therefore estimates has been made using data obtained on proteins considered to be as close in properties as possible to the peptide aptamers. Protocols and research papers have been extrapolated linearly, which is most often not possible. Therefore experiments should be conducted on both laboratory and pilot scale, and this proposal should only be taken as an indicator of the feasibility and competitiveness of the operation, and thereby the validity of carrying out the necessary experiments. Below is our process design. Click the boxes to dig deeper into each section.

A1: Autoclave

Figure 2: Autoclave A1
Before the fermentation can begin, the substrate must be sterilized to avoid contamination of the fermentation broth. For this procedure a batch sterilization has been chosen. To ensure sterility the feed is heated to 121 [°C], the pressure set at 2 [bar] and the residence time at 30 [min]. Reference: Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002 This was simulated in Aspen Plus using the BK10 method, and only the compounds available in the database were considered. The simulation showed a volume of the autoclave of 26.6 [L] and a heat duty of 48,483 [kJ/batch]. The substrate consist of Water (H2O), Glucose, Ammonium chloride (NH4Cl), Monopotassium phosphate (KH2PO4), Epsom salt (MgS·7 H2O), Calcium chloride dihydrate (CaCl2·2H2O), Ironsulphate (FeSO4), L-arganine·HCl, tracemetals and Ampicilin, the composition can be seen in table 1. The amount and composition of the substrate was based on a research artic le.. Reference: L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
Table 1: Composition and conditions for A1
S1: Feed 1 S2: Feed 1
Total mass [kg] 24.04 24.04
Temperature [°C] 21 121
Pressure [bar] 1 2
WT% H2O87.53 87.53
WT% Glucose 2.00 2.00
WT% NH4Cl0.13 0.13
WT% KH2PO41.50 1.50
WT% MgS·7 H2O0.01 0.01
WT% CaCl2·2H2O 0.01 0.01
WT% FeSO40.01 0.01
WT% L-arginine·HCI 0.80 0.80
WT% TraceMetals 8.00 8.00
WT% Ampicilin 0.01 0.01

E1: Heat exchanger
Figure 3: Heat exchanger E1

To avoid a flash occurring in the fermenter and ensure the survivel of cells, the substrate has to be cooled to 37 .[°C]. Reference: L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790 It has been chosen to grow the cells at this temperature, though growth at lower temperatures have been shown to decrease the amount of inclusion bodies formed. It has to be investigated at a later point if lower temperatures and the following prolongation of cycle time, could lead to an increase in production. Reference: Jeffrey Fu, David B. Wilson and Michael L. Shuler. Continuous, High Level Production and Excretion of a Plasmid-Encoded Protein by Escherichia coli in a Two-Stage Chemostat. Biotechnology and Bioengineering, 1993; 41: 937-946 As in A1 a simulation was run in Aspen Plus, the results showed the use of cooling water to be 5,474 [L/batch], and a heat duty of 15,196,014 [kJ/batch].

Table 2: Composition and conditions for E1
S1: Feed 1 S2: Feed 1
Total mass [kg] 24.04 24.04
Temperature [°C] 21 121
Pressure [bar] 1 2
WT% H2O 87.53 87.53
WT% Glucose 2.00 2.00
WT% NH4Cl0.13 0.13
WT% KH2PO41.50 1.50
WT% MgS·7 H2O0.01 0.01
WT% CaCl2·2H2O0.01 0.01
WT% FeSO40.01 0.01
WT% L-arginine·HCI 0.80 0.80
WT% TraceMetals 8.00 8.00
WT% Ampicilin 0.01 0.01

R1.1: Batch fermentation

Figure 4: Batch fermentation
Figure 5: Illustration of the scale up proce ss. Reference: L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
Fermentation is carried out under two conditions. In this first phase growth is carried out as a batch until glucose is depleted, and will take approximately 13 [h]. After which, cells will be grown to high densities in a fed-batch. One hindrance for accumulation of high biomass concentrations is the formation of inhibitors as acetate. By restricting the carbon source this formation can be reduced greatly, which can be viewed in figure 5. The figure describes the experimental results presented in the research paper used for estimates. The inoculum is scale linearly as in the case of the substrate. Therefore the same cell concentration is kept and the time will not be affected. The fed-batch and induction will be discussed further below. Reference: L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
Table 3: Composition and conditions for E1.1
S3: Feed 1 S4: innoculum R1: first phase
Total mass [kg] 24.04 1.72 25.76
Temperature [°C] 37 21 37
Pressure [bar] 1 1 1
WT% Dry cells 0.03 0.70
WT% H2O87.53 87.50 88.84
WT% Glucose 2.00 2.00
WT% NH4Cl0.13 0.13 0.13
WT% KH2PO41.50 1.50 1.50
WT% MgS·7 H2O0.01 0.01 0.01
WT% CaCl2·2H2O0.01 0.01 0.01
WT% FeSO40.01 0.01 0.01
WT% L-arginine·HCI 0.80 0.80 0.80
WT% TraceMetals 8.00 8.00 7.99
WT% Ampicilin 0.01 0.01 0.005


















A2: Autoclave

Figure 6: Autoclave A2

The substrate used for the fed-batch phase of the fermentation is sterilized in A2. The same type of sterilization and conditions as in the A1 are chosen. Simulation in Aspen Plus yielded a volume of 16.2 [L] and a heat duty of 7.457 [kJ/batch]. The composition of the substrate can be viewed in table 4. It should be noted that in order to avoid dilution of the cell concentration, the concentration of glucose is considerably higher than in S1.. Reference: L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790

Table 4: Composition and conditions for A2
S5: Feed 2 S6: Feed 2
Total mass [kg] 18.89 18.89
Temperature [°C] 21 121
Pressure [bar] 1 2
WT% H2O30.54 30.54
WT% Glucose 65.00 65.00
WT% NH4Cl0.50 0.50
WT% KH2PO40.17 0.17
WT% MgS·7 H2O0.75 0.75
WT% L-arginine·HCI 3.00 3.00
WT% Ampicilin 0.04 0.04

E2: Heat exchanger

Figure 7: Heat exchanger E2
The substrate of the fed-batch has to be cooled as in the case of E1. The same conditions are chosen, see table 5, and the exchanger was simulated in Aspen Plus. The simulation showed that 348 [L/batch] cooling water is needed, and that the heat duty is 4,016,502 [kJ/batch].
Table 5: Composition and conditions for E1
S6: Feed 2 S7: Feed 2
Total mass [kg] 18.89 18.89
Temperature [°C] 121 37
Pressure [bar] 2 1
WT% H2O30.54 30.54
WT% Glucose 65.00 65.00
WT% NH4Cl0.50 0.50
WT% KH2PO40.17 0.17
WT% MgS·7 H2O0.75 0.75
WT% L-arginine·HCI 3.00 3.00
WT% Ampicilin 0.04 0.04

R1.2: Fed-batch fermentation

Figure 8: Fed-batch fermentation
As mentioned above, the fed-batch facilitate high yield of dry cells. The experimental data from the research paper showed that a concentration of 75 [g dry cells/L] was reached after 27 [h]. This was deemed an appropriate level to start induction. The results also showed that substrate was fed in a rate, where glucose did not accumulate in the broth, and furthermore that the levels of acetate after an initial rise was non- existent in the end of the fed-batch phase, see figure 5: Batch fermentation. The composition of the fermentation broth before induction can be viewed in table 6. Reference: L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790

Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002
Table 6: Composition and conditions for R1.2
S7: Feed 2 R1: Second phase
Total mass [kg] 18.89 44.65
Temperature [°C] 37 37
Pressure [bar] 1 1
WT% Dry cells 7.50
WT% H2O30.54 84.59
WT% Glucose 65.00
WT% NH4Cl0.50 0.29
WT% KH2PO4 0.17 0.94
WT% MgS·7 H2O 0.75 0.32
WT% CaCl2·2H2O0.004
WT% FeSO40.01
WT% L-arginine·HCI 3.00 1.73
WT% TraceMetals 4.61
WT% Ampicilin 0.04 0.02

R1.3: Induction

Figure 9: Induction
Now the production of peptide aptamers can begin. The production is induced by Isopropyl-β-D- thiogalactoside (IPTG), which is added to a concentration of 2 [mM]. The target concentration of product will be discussed during the elution phase of the product recovery. The composition at start of induction and of the fermentation broth can be viewed in table 7. It was shown that inducing in the late log phase let to high yields of production, reducing the production phase to 4 [h]. Another benefit of the shortened residence time of the product, which reduces the risk of degradation by for example proteases. In the research paper the yield of product was reported to be 56 [mg/L] and the dry cell concentration was 92 [g/L]. Reference: L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790

Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002
Table 7: Composition and conditions for R1.3
R1: induction start S8: Fermentation broth
Total mass [kg] 44.64 44.64
Temperature [°C] 37 37
Pressure [bar] 1 1
WT% Peptide aptamer 0.01
WT% Dry cells 7.50 9.20
WT% H2O 84.54 82.89
WT% NH4Cl 0.29 0.29
WT% KH2PO4 0.94 0.94
WT% MgS·7 H2O 0.32 0.32
WT% CaCl2·2H2O 0.004 0.004
WT% FeSO4 0.01 0.01
WT% L-arginine·HCI 1.73 1.73
WT% TraceMetals 4.61 4.60
WT% Ampicilin 0.02 0.02
WT% IPTG 0.05

C1.1: Equilibration

Figure 10: Equilibration of C1
This is the first step of the product recovery. Before applying the fermentation broth to the column it needs to be fluidized. The fluidization process is described in greater detail during the next step. An important parameter for the creation of a stable bed is viscosity, should viscosities of the different buffers used vary in a degree that destabilizes the bed an inert viscous liquid will be added.. Reference: Pharmacia. Introduction to Expanded Bed Adsorption.
(Link) Accessed July 18th 2015]

The expansion is achieved be applying 10 bed volumes (BV) of column buffer (20 mM (4-(2- Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt) (Na-HEPES) and 500 mM Sodium chloride (NaCl)) at a flowrate of 300 [cm/h], which is recommended, though flows between 200 and 400 [cm/h] has been shown sufficient. The composition can be viewed in table 8. Determination of the BV relies on the production (see equation 1), it has been decided to produce 2 [g/batch] of the peptide aptamer. This decision will be elaborated in the decription of the elution step (C1.4). Reference: NEB-impact

Pharmacia. Introduction to Expanded Bed Adsorption.
(Link) Accessed July 18th 2015]

BV [L]=(binding capacity of the beads [g/L])/(mass of product [g] ) = 1.19 L (1)

To estimate the time needed for equilibration, we need to estimate the volume of the column. Expansion is reported to be 2-3 BV, therefore an expansion of 2.5 BV was chosen for calculations. Thus the column should be able to contain approximately 3 L. A column with a diameter of 50 [mm] is deemed to be appropriate for this process. To transfer this flowrate to a volumetric, it is calculated how large the volume is per cm, which is approximately 0.02[L]. This corresponds to a volumetric flowrate of 6 [L/h]. Now the time of application can be calculated to be 2 [h] and the height of the column to be 1.5 [m]. Reference: NEB-impact

Pharmacia. Introduction to Expanded Bed Adsorption.
(Link) Accessed July 18th 2015]

Table 8: Composition and conditions for C1.1
S9: equilibration S10: Waste
Total mass [kg] 11.88 11.88
Temperature [°C] 21 21
Pressure [bar] 1 1
WT% 96.60 96.60
WT% NaHEPES 0.48 0.48
WT% NaCl 2.92 2.92

C1.2: Application and wash

Figure 11: Application of fermentation broth and wash of C1
The benefit of the EBA is, that the fluidization leaves space between the beads for particulate matter to pass through. Rendering the solid separation steps of traditional product recovery unnecessary. This type of chromatography has been reported to be a one-step purification. Another benefit is the time reduction before the protein is bound to the beads, further reducing the residence time.. Reference: Pharmacia. Introduction to Expanded Bed Adsorption.
(Link) Accessed July 18th 2015]

The bed is fluidized by controlling the density of the beads, and thereby the downward force of sedimentation, and the upward force created by the flow. The sedimentation velocity is controlled by the design of the beads. In a stable bed the beads follow a Gaussian distribution. This is obtained by varying the density of the beads. Therefore the ordinary agarose beads are fitted with inert cores of varying diameters. An unstable bed leads to risk of turbulence or channelling, which will say that the feed does not have sufficient contact with the beads to bind the peptide aptamers efficiently. Reference: Pharmacia. Introduction to Expanded Bed Adsorption.
(Link) Accessed July 18th 2015]

In this step the fermentation broth is applied first, after which all impurities are washed out of the column by applying 20 BV of column buffer. The streams can be viewed in table 9. Reference: NEB-impact

Table 9: Composition and conditions for C1.2
S8: Fermentation broth S11: Wash S12: Waste
Total mass [kg] 44.64 23.75 68.39
Temperature [°C] 37 21 21
Pressure [bar] 1 1 1
WT% Peptide aptamer 0.01
WT% Dry cells 9.20 6.01
WT% H2O82.89 96.60 88.83
WT% NH4Cl 0.29 0.19
WT% KH2PO40.94 0.61
WT% MgS·7 H2O0.32 0.21
WT% CaCl2·2H2O0.004 0.0026
WT% FeSO40.01 0.01
WT% L-arginine·HCI 1.73 1.13
WT% TraceMetals 4.60 3.00
WT% Ampicilin 0.02 0.01
WT% NaHEPES 0.48 0.17
WT% NaCl 2.92 1.01

A3: Autoclave

Figure 12: Autoclave A3
It is assumed that all cells will be contained in S10 and S12 and should be sterilized.. The conditions during sterilization is the same as that of the A1 and A2. The simulation in Aspen Plus yields the following results: a volume of 80.2 [L] and a heat duty of 167,301,000 [kJ/batch].

Table 10: Composition and conditions for A3
S21: Waste S22: Waste
Total mass [kg] 80.27 80.27
Temperature [°C] 21 121
Pressure [bar] 1 2
WT% Dry cells 5.12 5.12
WT% H2O89.98 89.98
WT% NH4Cl0.16 0.16
WT% KH2PO40.52 0.52
WT% MgS·7 H2O0.18 0.18
WT% CaCl2·2H2O0.002 0.002
WT% FeSO40.005 0.005
WT% L-arginine·HCI 0.96 0.96
WT% TraceMetals 2.56 2.56
WT% Ampicilin 0.01 0.01
WT% NaHEPES 0.21 0.21
WT% NaCl 1.30 1.30

E3: Heat exchanger

Figure 13: Heat exchanger E3
Before releasing the waste stream to the ordinary waste water system, the pressure has to be lowered. Therefore the stream is cooled to ensure that the waste leaves as a liquid. This unit was simulated in Aspen Plus, the results are as follows: 14,854 [L/batch] cooling water is needed, and the heat duty is 172,581,480 [kJ/batch]. The composition does not change and can be viewed in table 11.

Table 11: Composition and conditions for E3
S22: Waste S23: Waste
Total mass [kg] 80.27 80.27
Temperature [°C] 121 99
Pressure [bar] 2 2
WT% Dry cells 5.12 5.12
WT% H2O89.98 89.98
WT% NH4Cl0.16 0.16
WT% KH2PO40.52 0.52
WT% MgS·7 H2O0.18 0.18
WT% CaCl2·2H2O0.002 0.002
WT% FeSO40.005 0.005
WT% L-arginine·HCI 0.96 0.96
WT% TraceMetals 2.56 2.56
WT% Ampicilin 0.01 0.01
WT% NaHEPES 0.21 0.21
WT% NaCl 1.30 1.30

C1.3: Cleavage

Figure 14: Cleavage of Intein
In this step Intein selfcleaves releasing the peptide aptamer. This is achieved by flushing the column with 3 BV of cleavage buffer (20 mM Na-HEPES, 500 mM NaCl, 50 mM threo-1,4-Dimercapto-2,3- butanediol (DTT)), where after the resin is left at room temperature for 16 h, therefore it is assumed that all buffer leaves the column as waste in this step. It has been reported, that product recovery is above 95%, therefore it is assumed that 95% will be cleav ed.. Reference: NEB-impact
Table 12: Composition and conditions for C1.3
S13: Cleavage S14: Waste
Total mass [kg] 3.76 3.76
Temperature [°C] 21 21
Pressure [bar] 1 1
WT% H2O95.83 95.83
WT% NaHEPES 0.48 0.48
WT% NaCl 2.92 2.92
WT% DTT 0.77 0.77
















C1.4: Elution

Figure 15: Elution of peptide aptamer
Now the product is ready to be eluted with column buffer. Since the peptide aptamers are an alternative to monoclonal antibodies, the concentration of the end product has been chosen by comparison of 50 products from Sigma-Aldrich. Concentrations of the antibodies range from 0.5-2 g/L, the most common concentration (39 out of 50) was found to be 2 g/L, thus making this the target concentration of PAST’s products. See pdf (Sigma-Aldrich antibodies) for details. Reference: NEB-impact Pharmacia. Introduction to Expanded Bed Adsorption.
(Link) Accessed July 18th 2015

Sigma-Aldrich. (Link) Accessed August 1st 2015.

Due to the changing productions and the decision to release the broth at a predefined viscosity, concentrations of the product in each batch will fluctuate. Therefore the aim is to produce 2.5 g of the peptide aptamer per batch. The wanted concentration is reached by measuring the concentration at the release of the broth and adjust the elution accordingly. This determines the volume of the elution, the result can be viewed in table 13. Elution is performed with column buffer. If this buffer is not suited for storage, it can be changed by dialysis, though for now it is assumed appropriate. Reference: NEB-impact

Pharmacia. Introduction to Expanded Bed Adsorption.
(Link) Accessed July 18th 2015]

Table 13: Composition and conditions for C1.4
S15: Elution S16: product
Total mass [kg] 1.19 1.19
Temperature [°C] 21 21
Pressure [bar] 1 1
WT% Peptide aptamer 0.20
WT% H2O96.60 96.40
WT% NaHEPES 0.48 0.48
WT% NaCl 2.92 2.92






C1.5: Regeneration

Figure 16: Regeneration of the column
The last step of the product recovery is regeneration of the column, which prepares it for the next batch. It has been reported that the resin can be reused 4-5 times, it is assumed that 4 times is appropriate. Regeneration is performed by washing the bed with 3 BV of stripping solution (0.3 M Sodium hydroxide (NaOH)) and then leaving the bed to soak for 30 minutes. After which the column is washed with additional 7 BV of the stripping solution, followed with 20 BV of water. Lastly 5 BV of column buffer is applied. Reference: NEB-impact

Table 14: Composition and conditions for C1.5
S17: Stripping S18: Water S19: Column buffer S20: Waste
Total mass [kg] 11.88 8.31 5.94 26.13
Temperature [°C] 21 21 21 21
Pressure [bar] 1 1 1 1
WT% H2O99.64 100 96.60 99.06
WT% NaHEPES 0.48 0.11
WT% NaCl 2.92 0.66
WT% NaOH 0.36 0.16
















Figure 17: Timeline illustrating the entire process.